Table 4.
Therapy Delay ≤12 h (n = 80) |
Therapy Delay >12–24 h (n = 65) |
Therapy Delay >24 h (n = 53) |
p-Value (<12 vs. 12–24 h) |
p-Value (<12 vs. >24 h) |
p-Value (12–24 vs. >24 h) |
|
---|---|---|---|---|---|---|
Age (years) | 62.0 (±13.72) | 61.2 (±16.06) | 64.1 (±15.28) | 0.670 | 0.410 | 0.310 |
APACHE II (points) | 32.7 (±9.38) | 36.2 (±9.31) | 32.7 (±11.53) | 0.028 | 0.994 | 0.078 |
SAPS II (points) | 64.2 (±19.26) | 56.1 (±14.93) | 56.7 (±16.96) | 0.007 * | 0.021 | 0.850 |
Ventilator days | 12.9 (±18.50) | 13.2 (±19.11) | 13.0 (±16.93) | 0.930 | 0.996 | 0.937 |
ICU stay (days) | 20.2 (±25.80) | 19.9 (±23.95) | 18.0 (±19.49) | 0.930 | 0.578 | 0.643 |
Hospital stay (days) | 28.1 (±39.99) | 32.1 (±42.71) | 25.0 (±29.98) | 0.560 | 0.609 | 0.293 |
ICU mortality (%) | 40 (50.0%) | 39 (60.0%) | 39 (73.5%) | 0.231 | 0.006 * | 0.123 |
Hospital mortality (%) | 45 (56.2%) | 40 (61.5%) | 42 (79.2%) | 0.430 | 0.006 * | 0.038 |
CytoSorb therapy delay (hours) | 6.8 (±4.50) | 20.4 (±3.99) | 54.6 (±25.92) | <0.001 * | <0.001 * | <0.001 * |
Number of CytoSorb adsorbers used (n) | 3.03 (±1.66) | 2.69 (±1.62) | 2.24 (±0.97) | 0.211 | 0.002 * | 0.082 |
Lactate T0 (mmol/L) | 4.73 (±3.48) | 5.11 (±3.90) | 4.38 (±3.55) | 0.540 | 0.574 | 0.292 |
Lactate T6 (mmol/L) | 5.09 (±3.63) | 5.05 (±3.67) | 3.80 (±3.00) | 0.940 | 0.034 | 0.046 |
Norepinephrine T0 (µg/kg/min) | 0.50 (±0.65) | 0.45 (±0.26) | 0.42 (±0.37) | 0.506 | 0.323 | 0.613 |
Norepinephrine T6 (µg/kg/min) | 0.64 (±0.46) | 0.54 (±0.35) | 0.50 (±0.40) | 0.153 | 0.083 | 0.647 |
Second catecholamine T0 (%) | 64 (80.0%) | 25 (38.0%) | 22 (41.5%) | <0.001 * | <0.001 * | 0.740 |
Hydrocortisone T0 (%) | 63 (78.7%) | 44 (67.6%) | 29 (56.6%) | 0.134 | 0.008 * | 0.235 |
Volume bolus used (mL/kg) | 75.0 (±25.8) | 81.6 (±28.8) | 78.0 (±27.6) | 0.122 | 0.510 | 0.444 |
Dynamic Scoring System (points) | 8.48 (±1.53) | 7.60 (±1.58) | 7.01 (±2.19) | 0.001 * | <0.001 * | 0.093 |
* = Statistically significant using Bonferroni-adjusted alpha critical value = 0.017.